NCT02387125 is a Phase 1 clinical trial of CMB305 in Sarcoma, sponsored by Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

Who is sponsoring NCT02387125?

NCT02387125 is sponsored by Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

What drugs are being tested in NCT02387125?

Interventions in NCT02387125: CMB305, G100, Metronomic CPA.

What condition does NCT02387125 study?

NCT02387125 studies Sarcoma, Melanoma, Non-small Cell Lung Cancer, Ovarian Cancer.

Is NCT02387125 still recruiting?

NCT02387125 is currently terminated. Last updated 1 July 2020.

Last reviewed 2020-07-01 · How we verify

NCT02387125

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Terminated Phase 1 Last updated 1 July 2020

What this trial tests

Phase 1 trial testing CMB305 in Sarcoma in 79 participants. Terminated before completion.

Timeline

28 February 2015

Primary endpoint
29 March 2019

29 March 2019

Quick facts

Lead sponsor	Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	79
Start date	28 February 2015
Primary completion	29 March 2019
Estimated completion	29 March 2019
Sites	8 locations across United States

Drugs / interventions tested

CMB305 — full drug profile →
G100 — full drug profile →
Metronomic CPA — full drug profile →

Conditions studied

Sarcoma — all drugs for Sarcoma →
Melanoma — all drugs for Melanoma →
Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) — full company profile →

Who can join

Adults 18 to 80, any sex, with Sarcoma or Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1b, open label, multi-center study of CMB305 (sequentially administered LV305 \[a dendritic cell-targeting viral vector expressing the NY-ESO-1 gene\] and G305 \[NY-ESO-1 recombinant protein plus GLA-SE\]) in patients with melanoma, sarcoma, ovarian cancer, or non-small cell lung cancer that express NY-ESO-1.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in ovarian cancer therapy.
Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. · · 2018 · cited 417× · PMID 29249039 · DOI 10.1007/s00280-017-3501-8
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, et al · · 2018 · cited 298× · PMID 29770138 · DOI 10.3389/fimmu.2018.00947
Recent clinical trends in Toll-like receptor targeting therapeutics.
Anwar MA, Shah M, Kim J, Choi S. · · 2019 · cited 209× · PMID 30450666 · DOI 10.1002/med.21553
Viral vector-based gene therapies in the clinic.
Zhao Z, Anselmo AC, Mitragotri S. · · 2022 · cited 171× · PMID 35079633 · DOI 10.1002/btm2.10258
Trial Watch: Toll-like receptor agonists in cancer immunotherapy.
Smith M, García-Martínez E, Pitter MR, Fucikova J, et al · · 2018 · cited 171× · PMID 30524908 · DOI 10.1080/2162402x.2018.1526250
Harnessing innate immune pathways for therapeutic advancement in cancer.
Hu A, Sun L, Lin H, Liao Y, et al · · 2024 · cited 150× · PMID 38523155 · DOI 10.1038/s41392-024-01765-9
Cancer immunotherapy beyond immune checkpoint inhibitors.
Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, et al · · 2018 · cited 140× · PMID 29329556 · DOI 10.1186/s13045-017-0552-6
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.
Iribarren K, Bloy N, Buqué A, Cremer I, et al · · 2016 · cited 98× · PMID 27141345 · DOI 10.1080/2162402x.2015.1088631

Verify or expand the search:

Other trials of CMB305

Trials testing the same drug.

NCT02609984 — Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma · Phase 2 · terminated

Other recruiting trials for Sarcoma

Currently open trials in the same condition.

NCT07402577 — Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot · recruiting
NCT07501026 — Preoperative Spatially Fractionated Radiation Therapy (SFRT) in Soft Tissue Sarcoma (neoSFRT-SARC) · Phase 2 · recruiting
NCT07359911 — Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patient · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07222735 — Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma · Phase 1 · recruiting

Other Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) trials

Trials by the same sponsor.

NCT03520959 — A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metasta · Phase 3 · terminated
NCT02501473 — Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymp · Phase 1, PHASE2 · terminated
NCT02609984 — Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma · Phase 2 · terminated
NCT02122861 — Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02387125 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Last refreshed: 1 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02387125.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing